Double primary malignancies could be divided into two categories, depending on the interval between tumor diagnoses. A secondary malignancy could be defined as a new cancer that has occurred as a result of previous treatment with radiation or chemotherapy. Second primary malignancy can occur at any age but it's commonly at old age. A 46 premenopausal female patient presented to our outpatient clinic complaining from a mass in her right breast, routine metastatic work-up for distant metastasis declared multiple hepatic metastases, RT renal mass, and bone metastases. Palliative radiotherapy to tender and weight bearing sites followed by 4 cycles of systemic chemotherapy FEC regimen were received. Tru-cut needle biopsy from renal mass detected renal cell carcinoma of clear cell type, the patient started sunitinib and tamoxifen with bisphosphonate (Zoledronic acid), assessment of the response revealed reduction of the size and number of HFLs, and the size of renal mass, so the patient was decided to do cytoreductive nephrectomy and then continued on TAM and sunitinib. Collectively, due to the rising incidence of multiple primary malignancies, further studies should be done not only for better clinical evaluation and treatments but also for accurate determination of possible causes, pathogenesis, effective managements and screening programs.
Introduction
In general, the incidence of double primary malignancy is not considered rare following Hodgkin disease treatment [3] , and 3.8%. At 10 years versus 7% at 15 years for patients treated with doxorubicin-based regimens for breast cancer [4] .
Meta-analyses demonstrated a frequency of second primary malignancy of 3% -5%, third malignancy as 0.5%, and fourth malignancy, namely, quadrant tumor (QT), as 0.3%, in different organ with different histogenesis [5] .
Double primary malignancies could be divided into two categories, depending on the interval between tumor diagnoses [6] . Synchronous malignancies were second tumors which have been occurring either simultaneously, or within 6 months after the first malignancy while metachronous malignancies were secondary tumors that have developed after 6 months, or even more than that from the first malignancy.
Warren and Gates [7] [8] [9] [10] defined the criteria for diagnosis of double primary malignancies based on histologic confirmation of primary and secondary tumors, there should be at least 2 cm of normal mucosa and separated by at least 5 years in time if both tumors in the same location, and the probability of second tumor being metastasis of the primary one must be excluded.
A secondary malignancy could be defined as a new cancer that has occurred as a result of previous treatment with radiation or chemotherapy. Depending on the schedule of treatment, the most common secondary cancers were skin cancer, breast cancer, acute leukemia, colorectal, lung and stomach cancer. Second primary malignancy can occur at any age but it's commonly at old age [11] .
We aimed from this case report to set forth a rare case of triple malignancy, and to what extent our treatment was successful especially the combination of tamoxifen and sunitinib. 
Case Report

Discussion
Not only environmental factors are responsible for the etiology of double malignancy but also genetic factors, previous chemotherapy, previous radiotherapy, hormonal treatments and others, these factors interacted together to result in these complicated lesions. Synchronous breast cancer and renal cell carcinoma is very rare and only few reported cases worldwide [12] . Eight cases of synchronous breast primaries with RCC was reported in a population based study done by Jiao F. et al. [12] , metachronous tumors of breast with renal primary have been reported in literature with both metastatic as well second primaries [13] .
Only 3% of metastatic RCC cases reported to have breast metastasis [14] , although both breast IDC and RCC were discovered synchronously but we considered our case as having metachronous tumors with early RCC that became metastatic and lastly developed breast cancer, in order to confirm both diagnoses; immunohistochemistry with vimentin and cytokeratin on paraffin breast block were done and was detected to be positive cytokeratin and negative vimentin, furthermore, immunohistochemistry to detect ER and PR on paraffin RCC block were done and detected to be negative.
Based on complete response to chemotherapy and hormonal treatment of breast cancer that was confirmed by PET/CT and the expected short survival from m RCC, we decided not to proceed to mastectomy. Although there is a controversy about the role of CN in m RCC patients receiving targeted therapy [15] as it doesn't change the clinical outcome, but our patient had an intermediate risk at presentation and received a 6-months period of pre-surgical targeted therapy that changed her risk into favorable one and subsequently was decided to do CN. Now, our patient achieved good clinical response with only solitary hepatic, and few asymptomatic bone metastases, good organ functions, and better performance status. Does our patient gain benefit from modified radical mastectomy, or radiofrequency for HFL? We prefer to continue on hormonal treatment and targeted therapy.
Conclusion
Due to the rising incidence of multiple primary malignancies, further studies should be done not only for better clinical evaluation and treatments but also for accurate determination of possible etiologies, pathogenesis, effective managements and screening programs.
